FIG. 1

Compound (VI f) Dose-Dependently Suppresses TNF Release from RAW Cells



FIG. 2

Compound (VI f) Dose-Dependently Suppresses HMGB1 Release from RAW Cells



FIG. 3

IC_{50} values for TNF Inhibition in RAW Cells

Compound	IC_{50} (μM)
Nicotine	~1
VI f	< 1
VI b	~ 1
XII b	~ 1
VI e	~ 1
VI g	> 10
XII a	> 100

FIG. 4
Compound (VI f) is Protective in the Mouse CLP Model of Septic Shock

	Carrier	Compound (VI f)
Day-1	13	13
Day 0	13	13
Day 1	9	12
Day 2	9	12
Day 3	9	12
Day 4	9	12
Day 5	7	12
Day 6	7	12
Day 7	7	12
Day 8	7	11
Day 9	7	11
Day 10	7	11
Day 11	7	11
Day 12	7	11
Day 13	7	11

Injection of Compund (VI f) or Carrier, b.l.d. *[what is b.l.d.?]*

FIG. 5

Inhibition of TNF production from LPS-stimulated human macrophages by Compounds VI d and VI f and Nicotine



FIG. 6

Does α-Bungarotoxin override Compound (VI f) inhibitory effect?